June 13, 2026
Tumor drama, but make it hopeful
Treating pancreatic tumours may have revealed cancer's master switch
Cancer breakthrough or headline hype? Commenters cheer, nitpick, and hunt the real receipts
TLDR: A new pancreatic cancer drug nearly doubled average survival in an early study, sparking rare emotional cheers from doctors. Commenters were split between celebrating a genuine breakthrough and calling the “cancer master switch” headline way too dramatic, while others rushed in with links and side-theories.
The science world basically had its own Oscar moment when doctors reportedly stood up and cheered over results for daraxonrasib, a new drug for pancreatic cancer — one of the deadliest and hardest-to-treat cancers. The big headline-grabber: patients in the study saw average survival jump from 6.7 months to 13.2 months. That’s the kind of number that makes a room full of usually reserved researchers lose their cool.
But in the comments, the real show began. One camp was fully in “huge win, no notes” mode, with users quickly posting a paywall-free link and even the clinical trial listing like internet detectives bringing the receipts. The vibe there was clear: less hype-policing, more “this could help real people, and that matters.”
Then came the title police. One commenter called the “master switch” framing flat-out hyperbolic, arguing this finding seems to apply to about 20% of tumors, not all cancer everywhere forever. Still, even the skeptic basically ended up at, “Fine, discovering a weak spot in 20% of cancers is still amazing,” which is the closest the internet gets to a standing ovation.
And because no thread is complete without a wild-card subplot, another commenter swerved into talk of electricity, body fields, and YouTube-famous research on turning cancer on and off with voltage changes. So yes: part celebration, part fact-check, part scientific side quest — classic comment-section chaos.
Key Points
- •Results for daraxonrasib were presented at an oncology conference in Chicago at the end of May.
- •The article says daraxonrasib is a treatment for pancreatic cancer.
- •Reported median survival increased from 6.7 months to 13.2 months with the drug.
- •The presentation prompted a spontaneous standing ovation from thousands of scientists attending the lecture.
- •The article describes daraxonrasib as a promising candidate for the first of a new class of cancer treatments.